SIGNIFOR LAR Rx
Generic Name and Formulations:
Pasireotide pamoate 20mg, 40mg, 60mg; pwd for IM inj after reconstitution.
Novartis Pharmaceuticals Corp
Indications for SIGNIFOR LAR:
Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.
Initially 40mg by IM inj every 4 weeks into the right or left gluteus; may increase dose to max 60mg after 3 months if GH and/or IGF-1 levels not normalized. If over-response to treatment, may decrease in 20mg decrements. Hepatic impairment: moderate (Child-Pugh B): initially 20mg every 4 weeks; max: 40mg every 4 weeks; severe (Child-Pugh C): avoid.
<18yrs: not established.
Risk of hyperglycemia; initiate or adjust antidiabetic treatment if occurs; reduce dose or discontinue if remains uncontrolled. Monitor HbA1c and FPG prior to initiation, weekly for first 3 months, 4–6 weeks after dose increase, and thereafter as indicated. Congenital long QT prolongation. Cardiac disease (including recent MI, CHF, unstable angina, significant bradycardia); monitor QT interval at 21 days. High-grade heart block. Hypokalemia and/or hypomagnesemia; correct and monitor electrolytes prior to starting and during therapy. Monitor liver tests prior to initiation, 2–3 weeks after, then monthly for 3 months, then as indicated. Discontinue if significant hepatic impairment develops. Monitor baseline ECG, pituitary function prior to initiation and periodically during treatment. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with antiarrhythmics or other drugs that may prolong the QT interval. May antagonize cyclosporine (adjust dose). May potentiate bromocriptine; dose reduction may be needed.
Cyclohexapeptide somatostatin analog.
Diarrhea, nausea, hyperglycemia, diabetes, cholelithiasis, headache, abdominal pain, fatigue; bradycardia, QT prolongation, pituitary hormone deficiency.
Single-use kit—1 (w. diluents, supplies)
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Case for Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Pioglitazone May Reduce Cardiovascular, Noncardiovascular Mortality in T2D
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure
- Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis